XEN1101 placebo drug product consists of a size 3 white opaque HPMC capsule (Capsugel VCaps® Plus White OP) containing 10mg of Avicel® PH102 (microscrystaline cellulose)
Sponsors
Xenon Pharmaceuticals Inc.
Conditions
Focal Onset Seizures
Phase 3
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
CompletedCTIS2022-502000-73-00
Start: 2023-08-11End: 2026-01-09Target: 168Updated: 2025-09-30
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
RecruitingCTIS2022-502281-25-00
Start: 2023-09-27Target: 197Updated: 2026-01-12